Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
Clin Nutr ; 42(4): 486-492, 2023 04.
Article in English | MEDLINE | ID: mdl-36857957

ABSTRACT

Tuberculosis (TB) is a leading infectious cause of death worldwide, despite ongoing efforts to limit its incidence and mortality. Although the European Region has made gains in TB incidence and mortality, it now contends with increasing numbers of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Malnutrition is a major contributor to the burden of TB and may also be directly caused or enhanced by the onset of TB. The presence of malnutrition may worsen TB and MDR/RR-TB related treatment outcomes and contribute to growing TB drug-resistance. Preventing and treating all forms of malnutrition is an important tool to limit the spread of TB worldwide and improve TB outcomes and treatment efficacy. We carried out a scoping review of the existing evidence that addresses malnutrition in the context of TB. Our review found malnutrition increased the risk of developing TB in high-burden settings and increased the likelihood of developing unfavorable treatment outcomes, including treatment failure, loss to follow-up, and death. The potential impact of nutritional care and improved nutritional status on patient prognosis was more difficult to evaluate due to heterogeneity of patient populations, treatment protocols, and treatment durations and goals. High-quality trials that consider malnutrition as a major risk factor and relevant treatment target when designing effective strategies to limit TB spread and mortality are needed to inform evidence-based practice. In TB patients, we suggest that widespread and regular nutritional screening, assessment, and counselling, has the potential to increase effectiveness of TB management strategies and improve patient quality of life, overall outcomes, and survival.


Subject(s)
Malnutrition , Tuberculosis, Multidrug-Resistant , Tuberculosis , Humans , Antitubercular Agents/therapeutic use , Quality of Life , Nutrition Assessment , Nutritional Status , Tuberculosis/complications , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Tuberculosis, Multidrug-Resistant/complications , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/epidemiology , Malnutrition/complications , Malnutrition/epidemiology , Malnutrition/therapy
4.
Clin Nutr ; 36(5): 1187-1196, 2017 10.
Article in English | MEDLINE | ID: mdl-28689670

ABSTRACT

Patients with cancer are at particularly high risk for malnutrition because both the disease and its treatments threaten their nutritional status. Yet cancer-related nutritional risk is sometimes overlooked or under-treated by clinicians, patients, and their families. The European Society for Clinical Nutrition and Metabolism (ESPEN) recently published evidence-based guidelines for nutritional care in patients with cancer. In further support of these guidelines, an ESPEN oncology expert group met for a Cancer and Nutrition Workshop in Berlin on October 24 and 25, 2016. The group examined the causes and consequences of cancer-related malnutrition, reviewed treatment approaches currently available, and built the rationale and impetus for clinicians involved with care of patients with cancer to take actions that facilitate nutrition support in practice. The content of this position paper is based on presentations and discussions at the Berlin meeting. The expert group emphasized 3 key steps to update nutritional care for people with cancer: (1) screen all patients with cancer for nutritional risk early in the course of their care, regardless of body mass index and weight history; (2) expand nutrition-related assessment practices to include measures of anorexia, body composition, inflammatory biomarkers, resting energy expenditure, and physical function; (3) use multimodal nutritional interventions with individualized plans, including care focused on increasing nutritional intake, lessening inflammation and hypermetabolic stress, and increasing physical activity.


Subject(s)
Malnutrition/diagnosis , Malnutrition/therapy , Neoplasms/therapy , Body Composition , Body Mass Index , Diet , Exercise , Health Care Costs , Humans , Nutrition Assessment , Nutritional Requirements , Nutritional Status , Nutritional Support , Prevalence , Terminology as Topic
5.
Clin Nutr ; 34(3): 335-40, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25799486

ABSTRACT

OBJECTIVE: To provide a consensus-based minimum set of criteria for the diagnosis of malnutrition to be applied independent of clinical setting and aetiology, and to unify international terminology. METHOD: The European Society of Clinical Nutrition and Metabolism (ESPEN) appointed a group of clinical scientists to perform a modified Delphi process, encompassing e-mail communications, face-to-face meetings, in group questionnaires and ballots, as well as a ballot for the ESPEN membership. RESULT: First, ESPEN recommends that subjects at risk of malnutrition are identified by validated screening tools, and should be assessed and treated accordingly. Risk of malnutrition should have its own ICD Code. Second, a unanimous consensus was reached to advocate two options for the diagnosis of malnutrition. Option one requires body mass index (BMI, kg/m(2)) <18.5 to define malnutrition. Option two requires the combined finding of unintentional weight loss (mandatory) and at least one of either reduced BMI or a low fat free mass index (FFMI). Weight loss could be either >10% of habitual weight indefinite of time, or >5% over 3 months. Reduced BMI is <20 or <22 kg/m(2) in subjects younger and older than 70 years, respectively. Low FFMI is <15 and <17 kg/m(2) in females and males, respectively. About 12% of ESPEN members participated in a ballot; >75% agreed; i.e. indicated ≥7 on a 10-graded scale of acceptance, to this definition. CONCLUSION: In individuals identified by screening as at risk of malnutrition, the diagnosis of malnutrition should be based on either a low BMI (<18.5 kg/m(2)), or on the combined finding of weight loss together with either reduced BMI (age-specific) or a low FFMI using sex-specific cut-offs.


Subject(s)
Consensus , Malnutrition/diagnosis , Nutritional Sciences/standards , Adipose Tissue/metabolism , Body Composition , Body Mass Index , Delphi Technique , Europe , Female , Humans , Male , Risk Factors , Societies, Scientific , Surveys and Questionnaires , Weight Loss
7.
Aliment Pharmacol Ther ; 38(7): 825-34, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23957710

ABSTRACT

BACKGROUND: Drug toxicity is a well-known cause of acute pancreatitis (AP). Although many drugs have been associated with AP, the magnitude of the risk of most of them remains largely unknown. AIM: To determine the pancreatotoxic risk of a wide range of drugs. METHODS: The hospital-based Berlin case-control surveillance study, including all 51 Berlin hospitals in a hospital network, ascertained 102 cases with idiopathic AP (IAP) and 750 controls between 2002 and 2011. Patients with IAP were thoroughly validated using anamnestic, clinical or laboratory data. Drug exposure was obtained in a face-to-face interview. Possible drug aetiology was assessed in individual patients through a standardised causality assessment applying the criteria of the World Health Organization. Drug risks were further quantified [odds ratios (OR) with 95% confidence intervals (CI)] in a case-control design with unconditional logistic regression analysis. RESULTS: The pancreatotoxic risk of several drugs, including azathioprine (OR 5.1; 95% CI 1.9-13.5), fenofibrate (OR 12.2; 95% CI 2.3-69.1), mesalazine (OR 3.3; 95% CI 1.1-9.5) or angiotensin-converting enzyme inhibitors, was corroborated by case-control analysis and causality assessment. Causality assessment suggested a pancreatotoxic potential, among others, for mercaptopurine or the seldom reported leflunomide, and alluded to a novel risk for tocilizumab. Case-control analysis showed an increased risk for two phytotherapeutics: harpagophytum and valerian radix. CONCLUSIONS: Our study quantified the pancreatotoxic risk of different drugs and phytotherapeutics. The findings corroborate previous results from the literature but also indicate risks for substances not previously reported, highlighting the need for further controlled studies on pancreatic toxicity.


Subject(s)
Drug-Related Side Effects and Adverse Reactions/epidemiology , Pancreatitis/chemically induced , Phytotherapy/adverse effects , Adult , Aged , Berlin/epidemiology , Case-Control Studies , Confidence Intervals , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Humans , Male , Middle Aged , Odds Ratio , Pancreatitis/epidemiology , Risk
8.
Med Klin Intensivmed Notfmed ; 108(5): 401-7, 2013 Jun.
Article in German | MEDLINE | ID: mdl-23681278

ABSTRACT

Acute pancreatitis is a frequent clinical entity in the West. About 80% of patients with acute pancreatitis develop edematous pancreatitis, while 20% develop necrotizing pancreatitis: The latter is a potentially life-threatening disease. In this case, early enteral nutrition has been shown to improve the course of the disease. Usually, gastric enteral nutrition with a polymeric formula via a nasogastric tube is possible; only in a minority of patients is jejunal feeding necessary owing to the high gastric residual volume. An elemental formula is useful for patients with significant intestinal maldigestion. If enteral feeding is not feasible within 5-7 days, (additional) parenteral nutrition has to be considered. Individualized--primary enteral--nutritional support is an essential part of a multimodal therapy in severe acute pancreatitis and it improves clinical outcome.


Subject(s)
Critical Care/methods , Enteral Nutrition/methods , Pancreatitis, Acute Necrotizing/therapy , Parenteral Nutrition, Total/methods , Amino Acids/metabolism , Antioxidants/administration & dosage , Combined Modality Therapy , Energy Intake/physiology , Food, Formulated , Humans , Nutritional Requirements/physiology , Pancreatic Extracts/administration & dosage , Pancreatitis, Acute Necrotizing/physiopathology , Prognosis , Treatment Outcome
9.
Internist (Berl) ; 53(8): 990-4, 2012 Aug.
Article in German | MEDLINE | ID: mdl-22614102

ABSTRACT

A 38-year-old female presented with symptoms of gastroenteritis including fatigue and epigastric pain. An abdominal ultrasound indicated on the basis of raised liver values showed multiple liver lesions. However, additional imaging using contrast-enhanced ultrasound (CEUS), computer tomography (CT) as well as a magnetic resonance tomography (MR) failed to clarify the diagnosis. A fine needle biopsy revealed the histological diagnosis of peliosis hepatis. After discontinuing oral contraceptive medication, follow-up showed a steady state with clinical well being for at least 24 months.Peliosis hepatis is a rare hepatic disorder involving "bloody cysts" in the liver. Aetiology and pathogenesis remain unclear, but medication or toxins as possible triggering factors are discussed. Different clinical courses have been reported, including total asymptomatic state, unspecific fatigue, epigastric pain, as well as fulminant cases with liver rupture and bleeding complications.


Subject(s)
Contraceptives, Oral, Hormonal/adverse effects , Gastroenteritis/chemically induced , Gastroenteritis/prevention & control , Peliosis Hepatis/chemically induced , Peliosis Hepatis/prevention & control , Adult , Diagnosis, Differential , Female , Gastroenteritis/diagnosis , Humans , Peliosis Hepatis/diagnosis
10.
Eur J Clin Nutr ; 65(6): 735-42, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21407248

ABSTRACT

BACKGROUND/OBJECTIVES: Nutritional intervention with oral nutritional supplements (ONS) has been shown to increase quality of life in malnourished patients. We investigated whether post-hospital supplementation with ONS is cost-effective according to international benchmarks in malnourished patients. SUBJECTS/METHODS: In total, 114 malnourished patients (50.6±16.1 years, 57 female) with benign gastrointestinal disease were included and randomised to receive either ONS for 3 months and dietary counselling at discharge (intervention, n=60) or only dietary counselling at discharge (control group, n=54). Nutritional status was assessed with Subjective Global Assessment. Intervention patients documented daily intake of ONS; quality of life was assessed with Short-Form (SF)-36 Health Survey and SF-36 values were transformed into health-status utilities. Quality-adjusted life years (QALYs) were calculated by adopting the area under the curve method. We used two different pricing scenarios for ONS (minimum price: [euro]2.30 and maximum: [euro]2.93/tetrapack). The incremental cost-effectiveness ratio (ICER) of supplementation with ONS was calculated for both price scenarios. All analyses were corrected for age and gender. RESULTS: Intervention patients consumed 2.4±0.8 ONS per day. Intervention and control patients did not differ in their health status utilities at baseline (0.594±0.017 vs 0.619±0.018), but after 3 months, the health status utilities were significantly higher in intervention patients than in control patients (0.731±0.015 vs 0.671±0.016, P=0.028). Intervention was associated with significantly higher costs (ICER: [euro]9497 and [euro]12,099/additional QALY, respectively) but deemed cost-effective according to international thresholds (< [euro]50,000/QALY). CONCLUSIONS: A 3-month intervention with ONS increases quality of life in malnourished patients. This treatment appears to be cost-effective according to international benchmarks.


Subject(s)
Dietary Supplements/economics , Energy Intake , Gastrointestinal Diseases/complications , Health Status , Malnutrition/drug therapy , Nutrition Therapy/economics , Quality-Adjusted Life Years , Adult , Area Under Curve , Cost-Benefit Analysis , Dietary Proteins/administration & dosage , Dietary Proteins/economics , Female , Humans , Male , Malnutrition/economics , Malnutrition/etiology , Middle Aged , Pilot Projects , Quality of Life , Treatment Outcome
13.
Clin Nutr ; 28(4): 428-35, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19464771

ABSTRACT

Assessment of the severity of acute pancreatitis (AP), together with the patient's nutritional status is crucial in the decision making process that determines the need for artificial nutrition. Both should be done on admission and at frequent intervals thereafter. The indication for nutritional support in AP is actual or anticipated inadequate oral intake for 5-7 days. This period may be shorter in those with pre-existing malnutrition. Substrate metabolism in severe AP is similar to that in severe sepsis or trauma. Parenteral amino acids, glucose and lipid infusion do not affect pancreatic secretion and function. If lipids are administered, serum triglycerides must be monitored regularly. The use of intravenous lipids as part of parenteral nutrition (PN) is safe and feasible when hypertriglyceridemia is avoided. PN is indicated only in those patients who are unable to tolerate targeted requirements by the enteral route. As rates of EN tolerance increase then volumes of PN should be decreased. When PN is administered, particular attention should be given to avoid overfeeding. When PN is indicated, a parenteral glutamine supplementation should be considered. In chronic pancreatitis PN may, on rare occasions, be indicated in patients with gastric outlet obstruction secondary to duodenal stenosis or those with complex fistulation, and in occasional malnourished patients prior to surgery.


Subject(s)
Malnutrition/therapy , Pancreatitis, Chronic/therapy , Pancreatitis/therapy , Parenteral Nutrition , Adult , Clinical Trials as Topic , Contraindications , Enteral Nutrition , Glutamine/administration & dosage , Humans , Hypertriglyceridemia/prevention & control , Middle Aged , Nutritional Status , Overnutrition/prevention & control , Pancreatitis/complications , Pancreatitis, Chronic/complications , Parenteral Nutrition/adverse effects , Parenteral Nutrition/standards , Treatment Outcome , Young Adult
14.
Ger Med Sci ; 7: Doc23, 2009 Nov 18.
Article in English | MEDLINE | ID: mdl-20049080

ABSTRACT

The main role of carbohydrates in the human body is to provide energy. Carbohydrates should always be infused with PN (parenteral nutrition) in combination with amino acids and lipid emulsions to improve nitrogen balance. Glucose should be provided as a standard carbohydrate for PN, whereas the use of xylite is not generally recommended. Fructose solutions should not be used for PN. Approximately 60% of non-protein energy should be supplied as glucose with an intake of 3.0-3.5 g/kg body weight/day (2.1-2.4 mg/kg body weight/min). In patients with a high risk of hyperglycaemia (critically ill, diabetes, sepsis, or steroid therapy) an lower initial carbohydrate infusion rate of 1-2 g/kg body weight/day is recommended to achieve normoglycaemia. One should aim at reaching a blood glucose level of 80-110 mg/dL, and at least a glucose level <145 mg/dL should be achieved to reduce morbidity and mortality. Hyperglycaemia may require addition of an insulin infusion or a reduction (2.0-3.0 g/kg body weight/day) or even a temporary interruption of glucose infusion. Close monitoring of blood glucose levels is highly important.


Subject(s)
Carbohydrates/administration & dosage , Fluid Therapy/methods , Fluid Therapy/standards , Nutrition Disorders/prevention & control , Parenteral Nutrition/methods , Parenteral Nutrition/standards , Practice Guidelines as Topic , Germany , Humans
15.
Eur J Clin Pharmacol ; 63(10): 917-25, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17665184

ABSTRACT

BACKGROUND: The role of the single nucleotide polymorphisms (SNPs) on positions 2677G>T/A and 3435C>T of the multi-drug-resistance gene 1 (MDR1) in inflammatory bowel disease (IBD) remains unclear. AIMS: To further elucidate the potential impact of MDR1 two-locus genotypes on susceptibility to IBD and disease behaviour. PATIENTS AND METHODS: Three hundred eighty-eight German IBD patients [244 with Crohn's disease (CD), 144 with ulcerative colitis (UC)] and 1,005 German healthy controls were genotyped for the two MDR1 SNPs on positions 2677G>T/A and 3435C>T. Genotype-phenotype analysis was performed with respect to disease susceptibility stratified by age at diagnosis as well as disease localisation and behaviour. RESULTS: Genotype distribution did not differ between all UC or CD patients and controls. Between UC and CD patients, however, we observed a trend of different distribution of the combined genotypes derived from SNPs 2677 and 3435 (chi(2) = 15.997, df = 8, p = 0.054). In subgroup analysis, genotype frequencies between UC patients with early onset of disease and controls showed significant difference for combined positions 2677 and 3435 (chi(2) = 16.054, df = 8, p = 0.034 for age at diagnosis >or=25, lower quartile). Herein the rare genotype 2677GG/3435TT was more frequently observed (odds ratio = 7.0, 95% confidence interval 2.5 - 19.7). In this group severe course of disease behaviour depended on the combined MDR1 SNPs (chi(2) = 16.101, df = 6, p = 0.017 for age at diagnosis >or=25). No association of MDR1 genotypes with disease subgroups in CD was observed. CONCLUSIONS: While overall genotype distribution did not differ, combined MDR1 genotypes derived from positions 2677 and 3435 are possibly associated with young age onset of UC and severe course of disease in this patient group.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Colitis, Ulcerative/genetics , Crohn Disease/genetics , Polymorphism, Single Nucleotide , ATP Binding Cassette Transporter, Subfamily B , Adult , Age of Onset , Anti-Inflammatory Agents/therapeutic use , Case-Control Studies , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/epidemiology , Crohn Disease/drug therapy , Crohn Disease/epidemiology , Disease Progression , Female , Gene Frequency , Genetic Predisposition to Disease , Germany/epidemiology , Glucocorticoids/therapeutic use , Haplotypes , Humans , Linkage Disequilibrium , Male , Middle Aged , Odds Ratio , Phenotype , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Treatment Outcome
16.
Aliment Pharmacol Ther ; 25(11): 1301-9, 2007 Jun 01.
Article in English | MEDLINE | ID: mdl-17509098

ABSTRACT

BACKGROUND: Alteration of the leptin system appears to play a role in the inflammatory-metabolic response in catabolic diseases such as chronic liver diseases. AIM: To investigate the association between leptin components, inflammatory markers and hepatic energy and substrate metabolism. METHODS: We investigated in vivo hepatic substrate and leptin metabolism in 40 patients employing a combination of arterial and hepatic vein catheterization techniques and hepatic blood flow measurements. In addition to metabolic, inflammatory and neuroendocrine parameters, circulating levels of free leptin, bound leptin and soluble leptin receptor were determined. RESULTS: Compared with controls, bound leptin and soluble leptin receptor levels were significantly elevated in cirrhosis, while free leptin did not increase. In cirrhosis bound leptin was correlated with soluble leptin receptor (r = 0.70, P < 0.001). Free leptin was positively correlated with metabolic parameters such as energy storage (body fat mass; r = 0.36, P < 0.05), insulin and insulin resistance (r = 0.48; r = 0.46, P < 0.01) as well as with hepatic glucose and energy release (r = 0.35 and r = 0.40, P < 0.05). In contrast, bound leptin and soluble leptin receptor were linked to proinflammatory cytokines and sympathetic activity (r = 0.61 and r = 0.56, P < 0.01). CONCLUSION: The components of the leptin system (free leptin, bound leptin and soluble leptin receptor) have distinct roles in metabolic and inflammatory processes in patients with liver cirrhosis. The better understanding of this metabolic and inflammatory tissue-repair response may lead to innovative new therapeutic strategies in liver disease as well as in various other catabolic diseases.


Subject(s)
Hepatitis/etiology , Leptin/physiology , Liver Cirrhosis/metabolism , Receptors, Leptin/metabolism , Adult , Case-Control Studies , Cytokines/metabolism , Female , Hepatitis/metabolism , Humans , Leptin/metabolism , Male , Middle Aged
17.
Clin Nutr ; 25(2): 330-60, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16735082

ABSTRACT

Nutritional intake is often compromised in elderly, multimorbid patients. Enteral nutrition (EN) by means of oral nutritional supplements (ONS) and tube feeding (TF) offers the possibility to increase or to insure nutrient intake in case of insufficient oral food intake. The present guideline is intended to give evidence-based recommendations for the use of ONS and TF in geriatric patients. It was developed by an interdisciplinary expert group in accordance with officially accepted standards and is based on all relevant publications since 1985. The guideline was discussed and accepted in a consensus conference. EN by means of ONS is recommended for geriatric patients at nutritional risk, in case of multimorbidity and frailty, and following orthopaedic-surgical procedures. In elderly people at risk of undernutrition ONS improve nutritional status and reduce mortality. After orthopaedic-surgery ONS reduce unfavourable outcome. TF is clearly indicated in patients with neurologic dysphagia. In contrast, TF is not indicated in final disease states, including final dementia, and in order to facilitate patient care. Altogether, it is strongly recommended not to wait until severe undernutrition has developed, but to start EN therapy early, as soon as a nutritional risk becomes apparent.


Subject(s)
Enteral Nutrition/standards , Geriatrics/standards , Malnutrition/therapy , Practice Patterns, Physicians' , Aged , Aged, 80 and over , Europe , Humans , Quality of Life
18.
Clin Nutr ; 25(2): 275-84, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16678943

ABSTRACT

The two major forms of inflammatory pancreatic diseases, acute and chronic pancreatitis, require different approaches in nutritional management, which are presented in the present guideline. This clinical practice guideline gives evidence-based recommendations for the use of ONS and TF in these patients. It was developed by an interdisciplinary expert group in accordance with officially accepted standards and is based on all relevant publications since 1985. The guideline was discussed and accepted in a consensus conference. In mild acute pancreatitis enteral nutrition (EN) has no positive impact on the course of disease and is only recommended in patients who cannot consume normal food after 5-7 days. In severe necrotising pancreatitis EN is indicated and should be supplemented by parenteral nutrition if needed. In the majority of patients continuous TF with peptide-based formulae is possible. The jejunal route is recommended if gastric feeding is not tolerated. In chronic pancreatitis more than 80% of patients can be treated adequately with normal food supplemented by pancreatic enzymes. 10-15% of all patients require nutritional supplements, and in approximately 5% tube feeding is indicated.


Subject(s)
Enteral Nutrition/standards , Gastroenterology/standards , Pancreatitis/therapy , Acute Disease , Europe , Humans , Pancreatitis, Chronic/therapy , Practice Patterns, Physicians'
19.
Clin Nutr ; 25(2): 319-29, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16698147

ABSTRACT

Undernutrition (wasting) is still frequent in patients infected with the human immunodeficiency virus (HIV), despite recent decreases in the prevalence of undernutrition in western countries (as opposed to developing countries) due to the use of highly active antiretroviral treatment. Undernutrition has been shown to have a negative prognostic effect independently of immunodeficiency and viral load. These guidelines are intended to give evidence-based recommendations for the use of enteral nutrition (EN) by means of oral nutritional supplements (ONS) and tube feeding (TF) in HIV-infected patients. They were developed by an interdisciplinary expert group in accordance with officially accepted standards and is based on all relevant publications since 1985. Nutritional therapy is indicated when significant weight loss (>5% in 3 months) or a significant loss of body cell mass (>5% in 3 months) has occurred, and should be considered when the body mass index (BMI) is <18.5 kg/m(2). If normal food intake including nutritional counselling and optimal use of ONS cannot achieve an adequate nutrient intake, TF with standard formulae is indicated. Due to conflicting results from studies investigating the impact of immune-modulating formulae, these are not generally recommended. The results obtained in HIV patients may be extrapolated to other chronic infectious diseases, in the absence of available data.


Subject(s)
Enteral Nutrition/standards , Gastroenterology/standards , HIV Wasting Syndrome/therapy , Practice Patterns, Physicians' , Wasting Syndrome/therapy , Europe , Humans
20.
Aliment Pharmacol Ther ; 23(9): 1337-45, 2006 May 01.
Article in English | MEDLINE | ID: mdl-16629939

ABSTRACT

BACKGROUND: Until now, hydrophilic and lipophilic vitamin preparations had to be administered separately during total parenteral nutrition. By addition of glycocholic acid, a vitamin supplement (Cernevit, Baxter, Heidelberg, Germany) was developed that combines all vitamins into one vial. However, little information exists about possible consequences of bile acid administration such as glycocholic acid, especially if liver disease is pre-existing. AIM: To evaluate the effects of total parenteral nutrition with a vitamin preparation containing high doses of glycocholic acid in patients with and without liver disease. METHODS: In a prospective, randomized-controlled trial, 74 patients, 36 of them with hepatobiliary disease, received total parenteral nutrition for 16 +/- 11 days, either with Cernevit or control vitamin supplements. Patients were closely monitored for clinical and biochemical parameters including serum bile acid profiles measured by high-performance liquid chromatography. RESULTS: Serum glycocholic acid increased in patients with liver disease treated with Cernevit, whereas total bile acids did not significantly change. Other liver function tests remained stable during treatment. No adverse events during Cernevit administration were noted except for a reversible slight increase of transaminases in one patient. CONCLUSIONS: Cernevit was well tolerated after repeated dosing, even in patients with severe liver disease. Apart from standard controls of liver biochemistry, no specific surveillance is necessary during treatment with Cernevit.


Subject(s)
Biliary Tract Diseases/therapy , Glycocholic Acid/administration & dosage , Liver Diseases/therapy , Parenteral Nutrition, Total/methods , Vitamins/administration & dosage , Adult , Aged , Aged, 80 and over , Bile Acids and Salts/blood , Chromatography, High Pressure Liquid/methods , Female , Glycocholic Acid/adverse effects , Humans , Male , Middle Aged , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...